期刊文献+

塞卡替尼的合成

Synthesis of saracatinib
原文传递
导出
摘要 目的:合成Src蛋白酪氨酸激酶抑制剂塞卡替尼,并对其工艺改进。方法:以2,4,6-三氟苯腈为原料,经氨解、水解、环合、取代得到塞卡替尼。结果:合成了塞卡替尼,目标产物结构经1H-NMR,MS确证,总收率为24.54%。结论:本方法具有可行性,适合工业化生产。 Objective: To synthesize the Src kinase inhibitor saracatinib, and optimize the synthetic process. Medthods: Saraeatinib was synthesized from 2,4 16-trifluorobenzonitrile through procedures of ammonolysis, hydrolysis, eyclization, and substitution. Results and Conclusion: Saraeatinib was synthesized with a total yield of 24.54% , and was verified by ^1H-NMR and MS. This synthetic method was suitable for large-scale production.
出处 《中国新药杂志》 CAS CSCD 北大核心 2011年第23期2363-2366,共4页 Chinese Journal of New Drugs
关键词 酪氨酸激酶抑制剂 塞卡替尼 合成 tyrosine kinase inhibitor saracatinib synthesis
  • 相关文献

参考文献10

  • 1白晓春,罗深秋,白洁.Src激酶的功能研究新进展[J].生命科学,2002,14(1):50-52. 被引量:4
  • 2HENNEQUIN LF,ALLEN J,BREED J,et al.N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-piperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine,a novel,highly,selective,orally available,dual-specific c-Src/Abl kinase inhibitor[J].J Med Chem.2006,49(22):6465-6488.
  • 3ISHIZANAR R,PARSONS SJ.c-Src and cooperating partners in human cancer[J].Cancer Cell.2004,6(3):209-214.
  • 4BISCARDI JS,ISHIZAWAR RC,SILVA CM,et al.Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer[J].Breast Cancer Res.2000,2(3):203-210.
  • 5YEATMAN TJ.A renaissance for SRC[J].Nat Rev Cancer.2004,4(6):470-480.
  • 6ZHU S,BIORGE JD,FUJITA DJ.PTP1B contributes to the oncongenic properties of colon cancer cells through Src activation[J].Cancer Res.2007,67(21):10129-10137.
  • 7PLE PA,GREEN TP,HENNEQUIN LF,et al.Discovery of a new class of anilinoquinazoline inhibitors with high affinify and specificify for the tyrosine kinase domain of c-Src[J].J Med Chem.2004,47(4):871-887.
  • 8FORD JG,O'KEARNEY-MCMULLAN A,POINTON SM,et al.Development of an efficient and practical route for the multikilogram manufacture of the SRC kinase inhibitor AZD0530[J].Org Process Res Dev.2010,14(5):1088-1093.
  • 9FORD JG,POINTON SM,POWELL L,et al.Process research and development for the kilogram manufacture of the SRC kinase inhibitor AZD0530[J].Org Process Res Dev.2010,14(5):1078-1087.
  • 10FORD JG,MCCABE JF,O'KEARNEY-MCMULLAN A,et al.Chemical Process.WO2006064217[P].2006-06-22.

二级参考文献8

  • 1[1]Thomas S M, Brugge J S. Annu Rev Cell Dev Biol,1997; 13: 513-609.
  • 2[2]Weiss A, Schiessinger J. Cell, 1998; 94: 277-280.
  • 3[3]Atkinson E A, Ostergaards H, Kanes K, et al. J Biol Chem, 1996; 271: 5968-5971.
  • 4[4]Wong B R, Besser D, Kim N, et al. Mol Cell, 1999;4: 1041-1049.
  • 5[5]Brunet A, Bonni A, Zigmond M J, et al. Cell, 1999;96: 857-868.
  • 6[6]Eliceiri B P, Paul R, Schwartzberg P L, et al. Mol Cell, 1999; 4: 915-924.
  • 7[7]Belka C, Martini P, Lepple-Wienhues A, et al. Oncogene, 1999; 18: 4983-4992.
  • 8[8]Yuan Z M, Shioya H, Ishiko T, et al. Nature, 1999;399: 814-817.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部